Inhibition of Experimental Melanin Protein-induced Uveitis (EMIU) by Targeting Nitric Oxide via Phosphatidylcholine-specific Phospholipase C

Matteson, Dawn M.; Shen, De Fen; Chan, Chi‐Chao

doi:10.1006/jaut.1999.0319

Cited by 14 publications

(10 citation statements)

References 36 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also noteworthy that the time of cytokine and iNOS expression was critical for the study of the mechanism. In a further study, such as the previous description [31] on the inhibition of EMIU [35], it may be important that the complex regulation of these cytokines and iNOS be considered.…”

Section: Discussionmentioning

confidence: 99%

The Expression of Multiple Cytokines and Inducible Nitric Oxide Synthase in Experimental Melanin-Protein-Induced Uveitis

Kim

Yoon²,

Joo³

2001

Ophthalmic Res

View full text Add to dashboard Cite

We investigated the kinetics of multiple cytokines and inducible nitric oxide synthase (iNOS) in experimental uveitis induced by bovine melanin protein (BMP) for the proper treatment of uveitis. Experimental uveitis was induced in male Lewis rats by injection of BMP. The levels of various inflammatory cytokines and iNOS mRNAs were semiquantified by the reverse-transcriptase reaction followed by PCR. The uveitis was started to develop at approximately day 14 and peaked around 21 days after immunization. The signs of uveitis disappeared by 4 weeks after immunization. When the inflammation was severest, TNF-α, IL-1α, IL-10, IFN-γ and iNOS mRNA increased to their peak, which varied with the degree of induction and different time course. We concluded that both cytokines and iNOS might modulate the inflammation at different states of experimental melanin-protein-induced uveitis. Their combination will be necessary for an effective treatment of inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

The Expression of Multiple Cytokines and Inducible Nitric Oxide Synthase in Experimental Melanin-Protein-Induced Uveitis

Kim

Yoon²,

Joo³

2001

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…According to Matteson et al (52) , this model can be induced by subcutaneous injection of melanin proteins in association with Hunter adjuvant. CD4+ T cells are the primary mediators of the inflammatory response, as well as in EAU (53) , but the target tissue is the uvea, where the melanocytes are located, not the retina.…”

Section: Experimental Melanin Protein-induced Uveitis (Emiu)mentioning

confidence: 99%

“…IL-2 and IFN-γ are the predominant intraocular cytokines produced early in the disease, then IL-12, and finally TNF-α at the peak of the inflammation. Other inflammatory mediators such as nitric oxide are also involved in the inflammatory response (40,52) . Yamaki et al described the induction of uveoretinitis in rats by peptides derived from tyrosinase, a melanocyte differentiation protein (56,57) .…”

Section: Experimental Melanin Protein-induced Uveitis (Emiu)mentioning

confidence: 99%

Experimental models of autoimmune inflammatory ocular diseases

Gasparin¹,

Takahashi²,

Scolari³

et al. 2012

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…In contrast, Uchio et al [40] showed that the same treatment was effective in reducing the severity of experimental autoimmune uveoretinitis. Both Chan's group [41] and Bora's group [42] conducted trials of inducible NO synthase inhibitors in rats with EMIU. Daily systemic treatments with D609 (5 mg/rat) or aminoguanidine (100 mg/kg) from the day of disease induction reduced the clinical and/or histological scores, but not the incidence, of uveitis.…”

Section: Evaluation Of Biologic Therapies For Uveitis: Studies With Emiumentioning

confidence: 99%

Experimental Melanin-Induced Uveitis: Experimental Model of Human Acute Anterior Uveitis

Smith

Rosenbaum²,

Williams

2008

Ophthalmic Res

View full text Add to dashboard Cite

Experimental melanin-protein-induced uveitis (EMIU), which is also known as experimental autoimmune anterior uveitis, was first described in 1993 by Broekhuyse et al. This experimental uveitis may be induced in certain inbred and outbred rat strains by immunization with bovine ocular melanin. The inflammation shares clinical features with human acute anterior uveitis. The duration of the first episode is approximately 1 month. Spontaneous recovery to a near normal clinical state is the rule, but multiple recurrences are common. Slit-lamp biomicroscopic examination reveals a florid anterior-chamber reaction, with formation of a retro-iridal empyema, fibrin clots and posterior synechiae. At a microscopic level, leukocytic infiltration is first observed in the anterior uvea. Although this tissue remains the site of maximum inflammation throughout an attack, in severe cases, limbitis, vitritis and choroiditis are also observed. Abrogation of EMIU occurs after treatment with anti-CD4 antibody, indicating that the uveitis is controlled by CD4-positive T cells. Several research groups have used EMIU to investigate various aspects of the pathogenesis of acute anterior uveal inflammation, including the participation of different leukocyte subsets, the expression of cell adhesion molecules, cytokines, chemokines and nitric oxide, the role of complement and the impact of apoptosis. In addition, EMIU has also been used to evaluate various biologic interventions with potential implications for the treatment of human disease.

show abstract

Inhibition of Experimental Melanin Protein-induced Uveitis (EMIU) by Targeting Nitric Oxide via Phosphatidylcholine-specific Phospholipase C

Cited by 14 publications

References 36 publications

The Expression of Multiple Cytokines and Inducible Nitric Oxide Synthase in Experimental Melanin-Protein-Induced Uveitis

The Expression of Multiple Cytokines and Inducible Nitric Oxide Synthase in Experimental Melanin-Protein-Induced Uveitis

Experimental models of autoimmune inflammatory ocular diseases

Experimental Melanin-Induced Uveitis: Experimental Model of Human Acute Anterior Uveitis

Contact Info

Product

Resources

About